Implementation of next-generation sequencing for hepatitis B virus resistance testing and genotyping in a clinical microbiology laboratory

Journal of Clinical Microbiology

Volumn 54, Issue 1, 2016, Pages 127-133

  Lowe, Christopher F ^a,b   Merrick, Linda ^a   Harrigan, P Richard ^c   Mazzulli, Tony ^d,e   Sherlock, Christopher H ^a,b   Ritchie, Gordon ^a,b  

^a Division of Microbiology and Virology   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

POL PROTEIN; VIRUS DNA;

ARTICLE; CLINICAL LABORATORY; CODON; CONTROLLED STUDY; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROBIOLOGY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; REPRODUCIBILITY; SANGER SEQUENCING; SEQUENCE ANALYSIS; VALIDATION STUDY; VIROLOGY; VIRUS RESISTANCE; CHEMISTRY; CHRONIC HEPATITIS B; COST; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MUTATION; PROCEDURES;

COSTS AND COST ANALYSIS; DNA, VIRAL; GENOTYPING TECHNIQUES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84954309462     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02229-15     Document Type: Article

References (28)

1. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608. http://dx.doi.org/10.1053/j.gastro.2009.08.063.
2. Guirgis BS, Abbas RO, Azzazy HM. 2010. Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 14:e941-e953. http://dx.doi.org/10.1016/j.ijid.2010.03.020.
3. Congly SE, Wong P, Al-Busafi SA, Doucette K, Fung SK, Ghali P, Fonseca K, Myers RP, Osiowy C, Coffin CS. 2013. Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres. Liver Int 33:1363-1369. http://dx.doi.org/10.1111/liv.12222.
4. Qutub MO, Germer JJ, Rebers SP, Mandrekar JN, Beld MG, Yao JD. 2006. Simplified PCR protocols for INNO-LiPA HBV genotyping and INNO-LiPA HBV PreCore assays. J Clin Virol 37:218-221. http://dx.doi.org/10.1016/j.jcv.2006.08.006.
5. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167-185. http://dx.doi.org/10.1016/j.jhep.2012.02.010.
6. Kim JH, Park YK, Park ES, Kim KH. 2014. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 20: 5708-5720. http://dx.doi.org/10.3748/wjg.v20.i19.5708.
7. Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM. 2013. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 58:890-901. http://dx.doi.org/10.1002/hep.26383.
8. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. 2009. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83:1718-1726. http://dx.doi.org/10.1128/JVI.02011-08.
9. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, EgholmM, Shafer RW. 2009. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199:1275-1285. http://dx.doi.org/10.1086/597808.
10. Rodriguez-Frías F, Tabernero D, Quer J, Esteban JI, Ortega I, Domingo E, Cubero M, Camós S, Ferrer-Costa C, Sánchez A, Jardí R, Schaper M, Homs M, Garcia-Cehic D, Guardia J, Esteban R, Buti M. 2012. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies link age of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One 7:e37874. http://dx.doi.org/10.1371/journal.pone.0037874.
11. Ciftci S, Keskin F, Cakiris A, Akyuz F, Pinarbasi B, Abaci N, Dincer E, Badur S, Kaymakoglu S, Ustek D. 2014. Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method. Diagn Microbiol Infect Dis 79:25-30. http://dx.doi.org/10.1016/j.diagmicrobio.2014.01.005.
12. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, Lu F, Lyon E, Voelkerding KV, Zehnbauer BA, Agarwala R, Bennett SF, Chen B, Chin EL, Compton JG, Das S, Farkas DH, Ferber MJ, Funke BH, Furtado MR, Ganova-Raeva LM, Geigenmüller U, Gunselman SJ, Hegde MR, Johnson PL, Kasarskis A, Kulkarni S, Lenk T, Liu CS, Manion M, Manolio TA, Mardis ER, Merker JD, Rajeevan MS, Reese MG, Rehm HL, Simen BB, Yeakley JM, Zook JM, Lubin IM. 2012. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 30:1033-1036. http://dx.doi.org/10.1038/nbt.2403.
13. Clinical and Laboratory Standards Institute. 2009. Molecular diagnostic methods for infectious diseases; approved guideline-2nd ed. CLSI Document MM3-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. 2006. Fatal postlymphoma chemotherapy hepatitis B reactivation second-arytothe emergenceof a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 81:969-972. http://dx.doi.org/10.1002/ajh.20737.
15. Lindstrom A, Odeberg J, Albert J. 2004. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42:4788-4795. http://dx.doi.org/10.1128/JCM.42.10.4788-4795.2004.
16. Burd EM. 2010. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev 23:550-576. http://dx.doi.org/10.1128/CMR.00074-09.
17. Homs M, Buti M, Tabernero D, Quer J, Sanchez A, Corral N, Esteban R, Rodriguez-Frias F. 2012. Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. World J Gastroenterol 18:6096-6105. http://dx.doi.org/10.3748/wjg.v18.i42.6096.
18. Niesters HG, Zoulim F, Pichoud C, Buti M, Shapiro F, D'Heuvaert N, Celis L, Doutreloigne J, Sablon E. 2010. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Che-mother 54:1283-1289. http://dx.doi.org/10.1128/AAC.00970-09.
19. Knapp DJ, McGovern RA, Poon AF, Zhong X, Chan D, Swenson LC, Dong W, Harrigan PR. 2014. "Deep" sequencing accuracy and reproduc-ibility using Roche/454 technology for inferring co-receptor usage in HIV-1. PLoS One 9:e99508. http://dx.doi.org/10.1371/journal.pone.0099508.
20. Bayliss J, Nguyen T, Lesmana CR, Bowden S, Revill P. 2013. Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease. Semin Liver Dis 33:113-121. http://dx.doi.org/10.1055/s-0033-1345714.
21. Chevaliez S, Rodriguez C, Pawlotsky JM. 2012. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303-1313. http://dx.doi.org/10.1053/j.gastro.2012.02.027.
22. Homs M, Caballero A, Gregori J, Tabernero D, Quer J, Nieto L, Esteban R, Buti M, Rodriguez-Frias F. 2014. Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. PLoS One 9:e112306. http://dx.doi.org/10.1371/journal.pone.0112306.
23. Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, Harrigan PR, Swenson LC. 2014. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 58:1165-1173. http://dx.doi.org/10.1093/cid/ciu019.
24. Homs M, Buti M, Quer J, Jardí R, Schaper M, Tabernero D, Ortega I, Sanchez A, Esteban R, Rodriguez-Frias F. 2011. Ultra-deep pyrose-quencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 39:8457-8471. http://dx.doi.org/10.1093/nar/gkr451.
25. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitisBvirus polymerase isassociated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51:2285-2292. http://dx.doi.org/10.1128/AAC.01499-06.
26. Becker EA, Burns CM, León EJ, Rajabojan S, Friedman R, Friedrich TC, O'Connor SL, Hughes AL. 2012. Experimental analysis of sources of error in evolutionary studies based on Roche/454 pyrosequencing of viral genomes. Genome Biol Evol 4:457-465. http://dx.doi.org/10.1093/gbe/evs029.
27. Ko SY, Oh HB, Park CW, Lee HC, Lee JE. 2012. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect 18:E404-E411. http://dx.doi.org/10.1111/j.1469-0691.2012.03951.x.
28. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. 2014. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res 42:e144. http://dx.doi.org/10.1093/nar/gku739.